Published in Vaccine Weekly, October 26th, 2005
According to a study from the United States, "Herpes simplex virus type 1 (HSV-1) glycoprotein gC (gC-1) is an immune evasion molecule that inhibits complement activation by binding C3b. Three assays were used to assess whether IgG antibodies produced by HSV-1 infection in humans block the interaction between C3b and gC-1. In two assays human IgG had no effect, while in one assay IgG partially inhibited Ob binding, which occurred at IgG concentrations approaching the upper limits of those found in human serum."
"Mice infected with HSV-1 produced antibodies that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly